Lykos

MAPS Moves Forward With New Leadership Model
Stakeholders Address Alleged Research Bias As Veterans Endorse MDMA-AT
Can Lykos Therapeutics Address MDMA-AT Safety Concerns Ahead of FDA Decision?
Lykos Responds to Opposition by FDA Advisors to MDMA-Assisted Therapy
How MAPS PBC Became Lykos Therapeutics and Raised $100M